These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J; Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443 [TBL] [Abstract][Full Text] [Related]
13. Saquinavir: major study shows survival benefit in treatment-naive patients. James JS AIDS Treat News; 1997 Jul; (No 274):6. PubMed ID: 11364463 [TBL] [Abstract][Full Text] [Related]
14. [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance]. MMW Fortschr Med; 2003 Dec; 145(50):60-1. PubMed ID: 14963980 [No Abstract] [Full Text] [Related]
18. Searching for the right dose of ritonavir-saquinavir. TreatmentUpdate; 2001 Sep; 13(5):3. PubMed ID: 11768860 [No Abstract] [Full Text] [Related]
19. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients. von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863 [TBL] [Abstract][Full Text] [Related]
20. Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease. Merry C; Mulcahy F; Barry M; Gibbons S; Back D AIDS; 1997 Feb; 11(2):268-9. PubMed ID: 9030388 [No Abstract] [Full Text] [Related] [Next] [New Search]